Early First-Line Bortezomib for Acute Antibody-Mediated Rejection: A Retrospective Review of Long-Term Outcomes From a Uniform Single-Center Protocol.
BACKGROUND Antibody-mediated rejection (ABMR) is a major complication of kidney transplantation. With the current standard of care, long-term graft survival is poor. Optimal treatment remains uncertain, and various protocols are being used. Bortezomib has been previously proposed as a candidate for ABMR treatment, but...